291 related articles for article (PubMed ID: 33767386)
1. Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS.
Deng HX; Zhai H; Shi Y; Liu G; Lowry J; Liu B; Ryan ÉB; Yan J; Yang Y; Zhang N; Yang Z; Liu E; Ma YC; Siddique T
Commun Biol; 2021 Mar; 4(1):396. PubMed ID: 33767386
[TBL] [Abstract][Full Text] [Related]
2. In vivo genome editing improves motor function and extends survival in a mouse model of ALS.
Gaj T; Ojala DS; Ekman FK; Byrne LC; Limsirichai P; Schaffer DV
Sci Adv; 2017 Dec; 3(12):eaar3952. PubMed ID: 29279867
[TBL] [Abstract][Full Text] [Related]
3. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model.
Duan W; Guo M; Yi L; Liu Y; Li Z; Ma Y; Zhang G; Liu Y; Bu H; Song X; Li C
Gene Ther; 2020 Apr; 27(3-4):157-169. PubMed ID: 31819203
[TBL] [Abstract][Full Text] [Related]
4. In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model.
Chen YA; Kankel MW; Hana S; Lau SK; Zavodszky MI; McKissick O; Mastrangelo N; Dion J; Wang B; Ferretti D; Koske D; Lehman S; Koszka K; McLaughlin H; Liu M; Marshall E; Fabian AJ; Cullen P; Marsh G; Hamann S; Craft M; Sebalusky J; Arnold HM; Driscoll R; Sheehy A; Luo Y; Manca S; Carlile T; Sun C; Sigrist K; McCampbell A; Henderson CE; Lo SC
Gene Ther; 2023 May; 30(5):443-454. PubMed ID: 36450833
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-Mediated Gene Correction to Understand ALS.
Yun Y; Ha Y
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471232
[TBL] [Abstract][Full Text] [Related]
6. Treatment of a Mouse Model of ALS by In Vivo Base Editing.
Lim CKW; Gapinske M; Brooks AK; Woods WS; Powell JE; Zeballos C MA; Winter J; Perez-Pinera P; Gaj T
Mol Ther; 2020 Apr; 28(4):1177-1189. PubMed ID: 31991108
[TBL] [Abstract][Full Text] [Related]
7. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
Abati E; Bresolin N; Comi G; Corti S
Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
[No Abstract] [Full Text] [Related]
8. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration.
Baskoylu SN; Yersak J; O'Hern P; Grosser S; Simon J; Kim S; Schuch K; Dimitriadi M; Yanagi KS; Lins J; Hart AC
PLoS Genet; 2018 Oct; 14(10):e1007682. PubMed ID: 30296255
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 guided rna based model for the treatment of Amyotrophic Lateral Sclerosis: A progressive neurodegenerative disorder.
Naveed M; Aqib Shabbir M; Aziz T; Hurraira HM; Fatima Zaidi S; Athar R; Chattha HA; Alharbi M; Alshammari A; Alasmari AF
Acta Biochim Pol; 2023 Sep; 70(3):643-653. PubMed ID: 37672770
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS).
Kruminis-Kaszkiel E; Juranek J; Maksymowicz W; Wojtkiewicz J
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562705
[TBL] [Abstract][Full Text] [Related]
11. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
[TBL] [Abstract][Full Text] [Related]
12. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly
Malik R; Meng H; Wongkongkathep P; Corrales CI; Sepanj N; Atlasi RS; Klärner FG; Schrader T; Spencer MJ; Loo JA; Wiedau M; Bitan G
J Biol Chem; 2019 Mar; 294(10):3501-3513. PubMed ID: 30602569
[TBL] [Abstract][Full Text] [Related]
13. Whole genomic analysis reveals atypical non-homologous off-target large structural variants induced by CRISPR-Cas9-mediated genome editing.
Tsai HH; Kao HJ; Kuo MW; Lin CH; Chang CM; Chen YY; Chen HH; Kwok PY; Yu AL; Yu J
Nat Commun; 2023 Aug; 14(1):5183. PubMed ID: 37626063
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
15. Verification of CRISPR editing and finding transgenic inserts by Xdrop indirect sequence capture followed by short- and long-read sequencing.
Blondal T; Gamba C; Møller Jagd L; Su L; Demirov D; Guo S; Johnston CM; Riising EM; Wu X; Mikkelsen MJ; Szabova L; Mouritzen P
Methods; 2021 Jul; 191():68-77. PubMed ID: 33582298
[TBL] [Abstract][Full Text] [Related]
16. Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair.
Ababneh NA; Scaber J; Flynn R; Douglas A; Barbagallo P; Candalija A; Turner MR; Sims D; Dafinca R; Cowley SA; Talbot K
Hum Mol Genet; 2020 Aug; 29(13):2200-2217. PubMed ID: 32504093
[TBL] [Abstract][Full Text] [Related]
17. CNS-derived extracellular vesicles from superoxide dismutase 1 (SOD1)
Silverman JM; Christy D; Shyu CC; Moon KM; Fernando S; Gidden Z; Cowan CM; Ban Y; Stacey RG; Grad LI; McAlary L; Mackenzie IR; Foster LJ; Cashman NR
J Biol Chem; 2019 Mar; 294(10):3744-3759. PubMed ID: 30635404
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.
Wang L; Yi F; Fu L; Yang J; Wang S; Wang Z; Suzuki K; Sun L; Xu X; Yu Y; Qiao J; Belmonte JCI; Yang Z; Yuan Y; Qu J; Liu GH
Protein Cell; 2017 May; 8(5):365-378. PubMed ID: 28401346
[TBL] [Abstract][Full Text] [Related]
19. Safeguarding genome integrity during gene-editing therapy in a mouse model of age-related macular degeneration.
Yin J; Fang K; Gao Y; Ou L; Yuan S; Xin C; Wu W; Wu WW; Hong J; Yang H; Hu J
Nat Commun; 2022 Dec; 13(1):7867. PubMed ID: 36550137
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy in Amyotrophic Lateral Sclerosis.
Fang T; Je G; Pacut P; Keyhanian K; Gao J; Ghasemi M
Cells; 2022 Jun; 11(13):. PubMed ID: 35805149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
